The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumor burden (HTB) indolent non-Hodgkin lymphoma (iNHL): A multicenter phase II study.
Andrew M. Evens
Consultant or Advisory Role - Millennium
Research Funding - Millennium
Mitchell Reed Smith
Research Funding - Millennium
Izidore S. Lossos
Research Funding - Millennium
Michael Mark Millenson
No relevant relationships to disclose
Jane N. Winter
Research Funding - Millennium
Steven T. Rosen
No relevant relationships to disclose
Leo I. Gordon
Research Funding - Millennium